Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Royal Victoria Hospital, Montréal, Québec, Canada.
Department of Critical Care Medicine, National Institutes of Health, Clinical Center, Bethesda, Maryland.
JAMA Intern Med. 2021 Mar 1;181(3):353-360. doi: 10.1001/jamainternmed.2020.8876.
Nasopharyngeal swab nucleic acid amplification testing (NAAT) is the noninvasive criterion standard for diagnosis of coronavirus disease 2019 (COVID-19). However, it requires trained personnel, limiting its availability. Saliva NAAT represents an attractive alternative, but its diagnostic performance is unclear.
To assess the diagnostic accuracy of saliva NAAT for COVID-19.
In this systematic review, a search of the MEDLINE and medRxiv databases was conducted on August 29, 2020, to find studies of diagnostic test accuracy. The final meta-analysis was performed on November 17, 2020.
Studies needed to provide enough data to measure salivary NAAT sensitivity and specificity compared with imperfect nasopharyngeal swab NAAT as a reference test. An imperfect reference test does not perfectly reflect the truth (ie, it can give false results). Studies were excluded if the sample contained fewer than 20 participants or was neither random nor consecutive. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used to assess the risk of bias.
Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed for the systematic review, with multiple authors involved at each stage of the review. To account for the imperfect reference test sensitivity, we used a bayesian latent class bivariate model for the meta-analysis.
The primary outcome was pooled sensitivity and specificity. Two secondary analyses were performed: one restricted to peer-reviewed studies, and a post hoc analysis limited to ambulatory settings.
The search strategy yielded 385 references, and 16 unique studies were identified for quantitative synthesis. Eight peer-reviewed studies and 8 preprints were included in the meta-analyses (5922 unique patients). There was significant variability in patient selection, study design, and stage of illness at which patients were enrolled. Fifteen studies included ambulatory patients, and 9 exclusively enrolled from an outpatient population with mild or no symptoms. In the primary analysis, the saliva NAAT pooled sensitivity was 83.2% (95% credible interval [CrI], 74.7%-91.4%) and the pooled specificity was 99.2% (95% CrI, 98.2%-99.8%). The nasopharyngeal swab NAAT had a sensitivity of 84.8% (95% CrI, 76.8%-92.4%) and a specificity of 98.9% (95% CrI, 97.4%-99.8%). Results were similar in secondary analyses.
These results suggest that saliva NAAT diagnostic accuracy is similar to that of nasopharyngeal swab NAAT, especially in the ambulatory setting. These findings support larger-scale research on the use of saliva NAAT as an alternative to nasopharyngeal swabs.
鼻咽拭子核酸扩增检测(NAAT)是非侵入性的 2019 年冠状病毒病(COVID-19)诊断标准。然而,它需要经过培训的人员,这限制了它的可用性。唾液 NAAT 是一种有吸引力的替代方法,但它的诊断性能尚不清楚。
评估唾液 NAAT 对 COVID-19 的诊断准确性。
在这项系统评价中,于 2020 年 8 月 29 日对 MEDLINE 和 medRxiv 数据库进行了搜索,以查找诊断性测试准确性的研究。最终的荟萃分析于 2020 年 11 月 17 日进行。
研究需要提供足够的数据,以衡量唾液 NAAT 的敏感性和特异性,与不完善的鼻咽拭子 NAAT 作为参考测试相比。不完美的参考测试并不能完全反映事实(即,它可能会产生错误的结果)。如果样本中少于 20 名参与者,或者既不是随机的也不是连续的,则排除研究。使用诊断准确性研究 2 工具评估偏倚风险。
系统评价和荟萃分析报告的首选报告项目用于系统评价,多位作者参与了审查的每个阶段。为了考虑到不完美的参考测试敏感性,我们在荟萃分析中使用了贝叶斯潜在类别双变量模型。
主要结果是汇总的敏感性和特异性。进行了两项二次分析:一项仅限于同行评议的研究,另一项事后分析仅限于门诊环境。
搜索策略产生了 385 条参考文献,有 16 项独特的研究被确定进行定量综合。meta 分析包括 8 项同行评议的研究和 8 篇预印本(5922 名独特患者)。患者选择、研究设计和患者入组时的疾病阶段存在显著差异。15 项研究包括门诊患者,9 项研究专门从门诊人群中招募,症状轻微或无症状。在主要分析中,唾液 NAAT 的汇总敏感性为 83.2%(95%可信区间[CrI],74.7%-91.4%),汇总特异性为 99.2%(95% CrI,98.2%-99.8%)。鼻咽拭子 NAAT 的敏感性为 84.8%(95% CrI,76.8%-92.4%),特异性为 98.9%(95% CrI,97.4%-99.8%)。次要分析结果相似。
这些结果表明,唾液 NAAT 的诊断准确性与鼻咽拭子 NAAT 相似,尤其是在门诊环境中。这些发现支持对唾液 NAAT 作为鼻咽拭子替代方法的更大规模研究。